T. Rowe Price Health Sciences Fund PRHSX Fund Analysis

| Medalist Rating as of | See T. Rowe Price Investment Hub

Morningstar’s Analysis PRHSX

Will PRHSX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

A leadership change tests a proven process.

Associate Analyst Natalia Arrigoni

Natalia Arrigoni

Associate Analyst

Summary

An impending lead-manager change creates uncertainty for this otherwise strong healthcare strategy, prompting a downgrade of the People Pillar to Average from Above Average. Longtime lead manager Ziad Bakri announced in December 2025 that he will leave T. Rowe Price in July 2026 after a decade at the helm. His departure is certainly a loss, but incoming lead manager Jeff Holford knows the process well and plans to stick with it, supporting the decision to maintain an Above Average Process rating.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Sponsor Center